The numbers behind the story
Q3 FY 25
October 04, 2024
Intimation of Loss of Share Certificate
Q2 FY 25
September 30, 2024
Outcome of Board Meeting
September 23, 2024
Intimation of Board Meeting and Closure of Trading Window
September 10, 2024
USFDA has classified the inspection as Voluntary Action Indicated for Pilerne Bardez, Goa formulation facility
September 01, 2024
Intimation regarding a change in Registered Office w.e.f. 01.09.2024
Advertisement Published in Newspapers regarding registered office shifted w.e.f. 01.09.2024
August 23, 2024
Intimation of Issue of Share Certificate
August 8, 2024
Change in Key Managerial personnel for determining and disclosure of material events
August 5, 2024
Intimation of Loss of Share Certificate
July 1, 2024
Intimation of Loss of Share Certificate
Q1 FY 25
June 30, 2024
Intimation of Board Meeting
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended June 30, 2024
Reconciliation of Share Capital as on June 30, 2024
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2024
Corporate Governance Report as on June 30, 2024
Closure of Trading Window
June 27, 2024
Intimation under Regulation 30 of LODR
June 26, 2024
Intimation of loss of Share Certificate
June 17, 2024
Resignation of Internal Auditor
Intimation of loss of Share Certificate
June 12, 2024
Intimation about the Issuance of “Letter of Confirmation in lieu of original share certificate(s) lost by Shareholder
May 31st, 2024
Resignation of KMP
Q4 FY 24
March 31, 2024
Annual Secretarial Compliance Certificate 2024
Related Party Transactions for half year ended 31.03.2024
Intimation of Board Meeting
Reconciliation of Share Capital as on March 31, 2024
Closure of Trading Window
Corporate Governance Report as on March 31, 2024
Certificate under Regulation 40(9) & 40 (10) of the SEBI (LODR) Regulations, 2015 for the financial year ended March 31, 2024
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2024
Compliance Certificate – Regulation 7(3) as on March 31, 2024
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2024
Familiarisation Programmes for the financial year 23-24
March 29, 2024
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Directors
March 27, 2024
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Resignation of Senior Managerial Personnel (‘SMP’)
January 17, 2024
Intimation about the Issuance of “Letter of Confirmation in lieu of original share certificate(s) lost by Shareholder.
January 11, 2024
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg.
Q3 FY 24
February 5, 2024
Outcome of the Board Meeting held on February 5, 2024
December 31, 2023
Reconciliation of Share Capital as on December 31, 2023
Intimation of Board Meeting
Statement of Investor Complaints Pursuant to Regulation 13(3) for the quarter ended December 31, 2023
Corporate Governance Report as on December 31, 2023
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2023
Closure of Trading Window
December 14, 2023
ICRA – Upgrading of credit rating
December 04, 2023
Sale of Strategic Investment (Optimas) made by the Company
November 24, 2023
Intimation about the loss/misplacement of Share Certificate
October 19, 2023
Intimation about the loss/misplacement of Share Certificate(s)
October 3, 2023
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - GST (Goods & Services Tax)
Q2 FY 24
September 30, 2023
Related Party Transactions for half year ended 30.09.2023
Intimation of Board Meeting
Reconciliation of Share Capital as on September 30, 2023
Corporate Governance Report as on September 30, 2023
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended September 30, 2023
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2023
Closure of Trading Window
September 21, 2023
Update On open offer
August 29, 2023
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Prasugrel Tablets USP, 5 mg and 10 mg.
August 14, 2023
Corrigendum to the Detailed Public Statement (DPS) – Open Offer
August 9, 2023
Outcome of Board Meeting dated August 9, 2023
August 4, 2023
Intimation of Board Meeting and Insider trading window close
August 2, 2023
Update On Sale Of Shares By Promoter To Ipca Laboratories Ltd.
July 28, 2023
Receipt Of CCI Approval For Acquisition Of Shares By Ipca Laboratories Ltd.
July 27, 2023
Intimation about the loss/misplacement of Share Certificate(s)
Q1 FY 24
June 30, 2023
Auditors Certificate on Reconciliation of Share Capital as on June 30, 2023
CG (Corporate Governance) report as on June 30, 2023
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2023
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended June 30, 2023
Intimation of Board Meeting
Closure of Trading Window
June 26, 2023
Re-appointment of Dr. Prakash A. Mody as the Chairman & Managing Director of the Company
Grant of Employee Stock Options under Unichem Employee Stock Option Scheme 2018
May 15, 2023
Board meeting for Audited results FY 2022-23
May 8, 2023
Intimation about the loss/misplacement of Share Certificate(s)
April 24, 2023
Press Release - April 24, 2023
Public Announcement - April 24, 2023
Disclosure Under Regulation 30 - April 24, 2023
April 19, 2023
Intimation about the loss/misplacement of Share Certificate(s).
Q4 FY 23
March 31, 2023
Annual Secretarial Compliance Certificate 2023
Related Party Transactions for half year ended 31.03.2023
Auditors report on Reconciliation of Share Capital as on March 31, 2023
CG (Corporate Governance) report as on March 31, 2023
Certificate under regulation 40(9) & 40 (10) of the SEBI (LODR) Regulations, 2015 for the financial year ended March 31, 2023
Familiarisation Programmes for the financial year 22-23
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2023
Compliance Certificate – Regulation 7(3) as on March 31, 2023
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended March 31, 2023
Closure of Trading Window
March 20, 2023
Board of Directors - update
Q3 FY 23
December 31, 2022
Intimation of Board Meeting
Reconciliation of Share Capital as on December 31, 2022
Closure of Trading Window
Corporate Governance Report as on December 31, 2022
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2022
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended December 31, 2022
Q2 FY 23
December 30, 2022
Closure of Trading Window
November 24, 2022
Related Party Transactions for half year ended 30.9.2022
October 14, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Extended Phenytoin Sodium Capsules USP, 100 mg.
September 30, 2022
Intimation of Board Meeting
Reconciliation of Share Capital as on September 30, 2022
Corporate Governance Report as on September 30, 2022
Statement of Investor Complaints Pursuant to Regulation 13(3) for the Quarter ended September 30, 2022
Compliance Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2022
Closure of Trading Window
September 22, 2022
Update on liquidation of strategic investment made by the Company
September 21, 2022
Resignation of Internal Auditor
September 19, 2022
ICRA – assigned credit rating for Rs. 176 crs
August 23, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for for Unichem’s Carbamazepine Tablets USP
August 16, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Quetiapine Extended-Release Tablets USP
August 9, 2022
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Labetalol Hydrochloride Tablets
Q1 FY 23
June 30, 2022
Intimation of Board Meeting
Reconciliation of Share Capital as on June 30, 2022
Corporate Governance Report as on June 30, 2022
Closure of Trading Window
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2022
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended June 30, 2022
May 19, 2022
Intimation of Board Meeting
May 10, 2022
Sale of Strategic Investment made by the Company
Q4 FY 22
May 25, 2022
Secretarial compliance report
March 31, 2022
Disclosure of Related Party Transactions on a consolidated basis for half year ended March 31, 2022
Reconciliation of Share Capital as on March 31, 2022
Corporate Governance Report as on March 31, 2022
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended March 31, 2022
Compliance Certificate – Regulation 7(3) as on March 31, 2022
Q3 FY 22
December 31, 2021
Financial Results for the quarter and nine months ended December 31, 2021 published
in the newspapers on January 31, 2022.
Reconciliation of Share Capital as on December 31, 2021
Intimation of Board Meeting
Corporate Governance Report as on December 31, 2021.
Statement
of Investor Complaints Pursuant to Regulation 13(3)
for Quarter ended December 31, 2021
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended December 31,
2021
Closure of Trading Window
December 2, 2021
ANDA approval for Aripiprazole Tablets
Q2 FY 22
September 30, 2021
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended
September 30, 2021
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended September 30,
2021
Corporate Governance Report as on September 30,
2021.
Notice of Trading Window Close
Intimation of Board Meeting
Reconciliation of Share Capital as on September 30,
2021
Related Party Transactions
July 31, 2021
Voting results and Scrutinizer’s report.
Outcome of 58th Annual General Meeting
Proceeding.
Q1 FY 22
June 30, 2021
Intimation of Board Meeting.
Corporate Governance Report as on June 30, 2021.
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter ended June 30, 2021
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended June 30, 2021
Tentative Approval for ANDA from United States Food and Drug
Administration (USFDA) for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100
mg.
Reconciliation of Share Capital as on June 30, 2021.
Tentative Approval for ANDA from United States Food and Drug Administration (USFDA)
for Aripiprazole Tablets, USP, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg
Notice of Trading Window Close
Q4 FY 21
March 31, 2021
Disclosure Of Related Party Transactions On Consolidated Basis For Half Year Ended
March 31, 2021
Annual Secretarial Compliance Report of the Company for the
year ended March 31, 2021
Reconciliation of Share Capital as on March 31, 2021
Corporate Governance Report as on March 31, 2021
Certificate under regulation 40(9) & 40 (10) as on March 31,
2021
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter ended March 31, 2021
Compliance Certificate – Regulation 7(3) as on March 31, 2021
Certificate under regulation 74(5) of the SEBl (Depositories and Participants)
Regulations. 2018 for the quarter ended March 31, 2021
Familiarization Programme or Directors for FY 2020 -
2021
Closure of Trading Window
March 4, 2021
ANDA approval from United States Food and Drug Administration
(USFDA) for Unichem’s Guanfacine Tablets, USP 1 mg and 2 mg.
January 27, 2021
ANDA approval from United States Food and Drug Administration
(USFDA) for Unichem’s Apremilast Tablets, 10 mg, 20 mg and 30 mg.
ANDA approval from United States Food and Drug Administration
(USFDA) for Unichem’s Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg.
Q3 FY-21
Intimation of Board Meeting.
Reconciliation of Share Capital as on December 31, 2020.
Closure of Trading Window.
Corporate Governance Report as on December 31, 2020.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2020.
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2020.
January 13, 2021
ANDA approval from USFDA for Unichem’s Celecoxib Capsules, 50
mg, 100 mg, 200 mg, and 400 mg.
January 8, 2021
ICRA – assigned credit rating for Rs. 146 crs (Reduced from Rs. 150 crs) bank
facilities
Q2 FY-21
September 30, 2020
Disclosure
of Related Party Transactions for half year ended September 30, 2020.
Reconciliation of Share Capital as on September 30,
2020.
Intimation of Board Meeting
Certificate under regulation 40(9) & 40 (10) as on September
30, 2020
Corporate Governance Report as on September 30, 2020
Closure of Trading Window
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter ended September 30, 2020
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended September 30,
2020
Compliance Certificate – Regulation 7(3) as on September 30, 2020
July 10, 2020
ANDA approval from USFDA for Unichem’s Baclofen
Tablets
Q1 FY-21
June 30, 2020
Reconciliation of Share Capital as on June 30,
2020.
Notice of Board Meeting
Corporate Governance Report as on June 30, 2020
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter ended June 30, 2020
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended June 30, 2020
Closure of Trading Window
Q4 FY-20
March 31, 2020
Notice of Board Meeting
Reconciliation of Share Capital as on March 31,
2020.
Compliance Certificate – Regulation 7(3) as on March 31, 2020
Certificate under regulation 40(9) & 40 (10) as on March 31,
2020
Corporate Governance Report as on March 31, 2020.
Familiarization Programme 2019-2020
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended
March 31, 2020
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended March 31,
2020.
March 30, 2020
Intimation of closure of Trading Window
February 24, 2020
Announcement
under Regulation 30 of LODR
January 3, 2020
Credit Rating from ICRA
Initial Intimation Letter
Revised Intimation Letter
Q3 FY-20
December 31, 2019
Notice of Board meeting
Reconciliation of Share Capital as on December 31,
2019.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended
December 31, 2019
Corporate Governance Report as on December 31, 2019.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended
December 31, 2019
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended December 31,
2019.
Closure of Trading Window.
November 2, 2019
ANDA
approval from USFDA for Unichem’s Atenolol Tablets USP
Q2 FY-20
September 30, 2019
Related Party disclosures for half year ended September 30,
2019.
Reconciliation of Share Capital as on September 30,
2019.
Notice of
Board meeting
Certificate under regulation 74(5) of the SEBl (Depositories
and Participants) Regulations. 2018 for the quarter ended September 30,
2019.
Corporate
Governance Report as on September 30, 2019
Compliance Certificate – Regulation 7(3) as on September 30,
2019
Certificate under regulation 40(9) & 40 (10) as on
September 30, 2019
Statement
of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30,
2019
Closure of Trading Window
September 20, 2019
USFDA
approval for Kolhapur plant
September 6, 2019
USFDA
approval for Pithampur plant
August 26, 2019
USFDA
approval for the Company’s Ghaziabad plant
August 12, 2019
ANDA
approval from USFDA for Unichem’s Chlorthalidone Tablets
July 31, 2019
Retirement
of Company Secretary
July 27, 2019
Outcome of 56TH AGM
Proceedings
Voting
results and Scrutinizer’s report
July 5, 2019
Setting up of a Wholly Owned Subsidiary in China
Q1 FY-20
June 30, 2019
Reconciliation of
Share Capital as on June 30, 2019.
Certificate
under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018
for the quarter ended June 30, 2019.
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter ended June 30, 2019.
Corporate
Governance Report as on June 30, 2019.
Closure of Trading Window
Notice of
Board Meeting
May 3, 2019
Board meeting May 03, 2019
Update on board meeting
Q4 FY-19
March 28, 2019
March 13, 2019
March 11, 2019
February 26, 2019
Q3 FY-19
December 13, 2018
November 14, 2018
October 22, 2018
EIR for Unichem’s API manufacturing facilities at Pithampur and Roha
Q2 FY-19
September 30, 2018
Corporate Governance Report as on September 30, 2018
Reconciliation of Share Capital as on September 30, 2018
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30, 2018
Compliance Certificate – Regulation 7(3) as on September 30, 2018
Certificate under regulation 40(9) & 40 (10) as on September 30, 2018
September 24, 2018
July 3, 2018
Financial Statements of Subsidiaries for the financial year ended 2017-2018
Niche Genercis Limited
Unichem Farmaceutica Do Brazil Ltda
Unichem Laboratories Limited- Ireland
Unichem Pharmaceutical (USA), Inc.
Unichem SA (Propreitary) Limited
Q1 FY-19
June 20, 2018
Unichem has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the United States District Court for the District of New Jersey regarding Unichem’s Abbreviated New Drug Application for generic tadalafil (Cialis®). Under the settlement agreement, Unichem expects to launch its generic tadalafil product in the United States on or not before March 26, 2019 under certain circumstances.
June 6, 2018
Unichem’s formulation manufacturing facility at Ghaziabad has received an Establishment Inspection Report (EIR) from USFDA indicating closure of inspection. The inspection was conducted by FDA in April 2018.
May 29, 2018
Notice to Stock Exchanges
News paper advertisement
Notice
Sakhal
Notice
Business Standard
Q4 FY-18
February 5, 2018
Interim Audited Consolidated Financial Statements for the nine months period ended
December 31, 2017 and Record date ascertaining the Shareholders eligible for
Buyback.
Newspaper publication of the Notice for Board meeting
scheduled on 5.2.2018
Notice of Board meeting scheduled on February 5,
2018
January 3, 2018
Notice
of BuyBack
Q3 FY-18
Q2 FY-18
September 30, 2017
Newspaper advertisement of the Unaudited financial results for the quarter and half
year ended September 30, 2017
Notice of
Board Meeting
Board
meeting postponed
Notice of Board
Meeting
Reconciliation of Share Capital as on September 30,
2017
Corporate Governance Report as on September 30,
2017
Certificate under regulation 40(9) & 40 (10) as on
September 30, 2017
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter September 30, 2017
Compliance Certificate – Regulation 7(3) as on September 30, 2017
Q1 FY-18
June 30, 2017
Newspaper Advertisement of Unaudited Standalone Financial results (Business Standard
& Sakal)
Notice of
Board Meeting
Reconciliation of Share Capital as on June 30,
2017
Corporate
Governance Report as on June 30, 2017
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter June
30, 2017
April 17, 2017
The Company has received ANDA approval from the United States Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg & 20mg, which are therapeutically equivalent to Feldene Capsules 10mg & 20mg of Pfizer, Inc. Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA). For the relief of rheumatoid arthritis and osteoarthritis, the dosage is 20 mg given orally once daily. If desired, the daily dose may be divided. Usually lowest effective dosage for the shortest duration, consistent with individual patient treatment goals is recommended. The product will be commercialized from Unichem’s Goa plant. Active Pharmaceutical Ingredient will also be made in house at Roha API Plant.
Q4 FY-17
March 31, 2017
Newspaper
Advertisement of Audited Financial results for Q4 & Year End FY
2017
Notice of Board Meeting – Newspaper Advertisement.
Notice of Board
Meeting
Corporate Governance Report as on March 31, 2017
Reconciliation of Share Capital as on March 31, 2017
Certificate under regulation 40(9) & 40 (10) as on March
31, 2017
Statement of Investor Complaints Pursuant to Regulation 13(3)
as on March 31, 2017
Compliance Certificate – Regulation 7(3) as on March 31,
2017
March 20, 2017
The Company’s Formulation manufacturing facility at Goa was inspected by USFDA from March 14th 2017 to March 20th 2017. There were few observations made, and these in the opinion of the Company are correctable ones in respect to which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.
March 8, 2017
Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt – MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.
March 6, 2017
The Company’s formulation manufacturing facility at Ghaziabad was inspected by the USFDA from February 24, 2017 to March 3, 2017. The two observations cited are, in the opinion of the Company, correctable ones in respect of which the Company will file the necessary response within the stipulated period of 15 working days. The observations do not impact business continuity and the Company’s supplies to the US market.
Q3 FY-17
December 31, 2016
Reconciliation of Share Capital as on December 31, 2016
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter December 31, 2016
Notice of Board Meeting – Newspaper Advertisement
Newspaper
Advertisement of Unaudited Standalone Financial results (Business
Standard)
Notice of Board Meeting
Corporate Governance Report as on December 31, 2016
Q2 FY-17
September 30, 2016
Corporate Governance Report as on September 30, 2016
Reconciliation of Share Capital as on September 30,
2016
Certificate
under regulation 40(9) & 40 (10) as on September 30, 2016
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter September 30, 2016
Compliance
Certificate – Regulation 7(3) as on September 30, 2016
Notice of Board Meeting Newspaper Advertisement of the Board
meeting (Pratyaksha)
Newspaper
Advertisement of the Board meeting (Business Standard)
August 13, 2016
July 26, 2016
July 23, 2016
Q1 FY-17
May 20, 2016
April 21, 2016
April 19, 2016
Q4 FY-16
March 31, 2016
Corporate Governance Report as on March 31, 2016
Reconciliation of Share Capital as on March, 2016
Certificate under regulation 40(9) & 40 (10) as on March 31,
2016
Statement of Investor Complaints Pursuant to Regulation 13(3)
for Quarter March 31, 2016
Compliance Certificate – Regulation 7(3) as on March 31,
2016
March 03, 2016
December 31, 2018